IP Library › Granted Patent US 12,397,167
Granted Patent B2
US 12,397,167 · App. 18/526,789 · Granted Aug 26, 2025

Compositions and methods of altering the electric impedance to an alternating electric field

Inventors: Hadas Hershkovich (Haifa, IL); Tali Voloshin-Sela (Haifa, IL); Ze'ev Bomzon (Haifa, IL)
Assignee: NOVOCURE GMBH
A61N1/406A61N1/327A61N1/36002G06T7/0012G06T2207/30096
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,167
App. No.
18/526,789
Granted
Aug 26, 2025
Kind
B2
Abstract

Disclosed are methods of altering the electric impedance to an alternating electric field in a target site of a subject, comprising introducing a nanoparticle to a target site in the subject; and applying an alternating electric field to the target site of the subject, wherein the electric impedance in the target site of the subject to the alternating current is altered. Disclosed are methods for improving transport of a nanoparticle across a cell membrane of a cell, the method comprising applying an alternating electric field to the cell for a period of time, wherein application of the alternating electric field increases permeability of the cell membrane; and introducing the nanoparticle to the cell, wherein the increased permeability of the cell membrane enables the nanoparticle to cross the cell membrane. Disclosed are methods of imaging a cancer cell, the method comprising applying a first alternating electric field at a first frequency to the cancer cell for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cell for the first period of time increases permeability of cell membranes of the cancer cell; introducing a nanoparticle to the cancer cell, wherein the increased permeability of the cell membranes enables the nanoparticle to cross the cancer cell membrane; and imaging the cancer cell.

Claims (18)

1. A method of increasing the efficacy of an alternating electric field in a tumor target site of a subject, the method comprising:

a. introducing a conductive nanoparticle to a tumor target site in the subject;

b. applying an alternating electric field to the tumor target site, wherein the tumor target site is adjacent to one or more cancer cells,

wherein the alternating electric field has a frequency of 50 to 400 kHz,

wherein the efficacy of the alternating electric field in the tumor target site of the subject is increased,

wherein the increased efficacy of the alternating electric field in the tumor target site results in an increased anti-mitotic effect of the alternating electric field in the tumor target site.

2. The method of claim 1 , wherein the alternating electric field has a current density, wherein a magnitude of the current density of the alternating electric field is increased in the tumor target site.

3. The method of claim 1 , wherein the tumor target site has a lowered electric impedance.

4. The method of claim 1 , wherein the tumor target site has an increased conductivity.

5. The method of claim 1 , wherein the impedance in the site adjacent to the tumor target site is increased.

6. The method of claim 1 , wherein the alternating electric field is a tumor-treating field.

7. The method of claim 1 , further comprising introducing a non-conductive nanoparticle to a site adjacent to the tumor target site in the subject.

8. The method of claim 7 , wherein the tumor target site has an increased electric impedance.

9. The method of claim 7 , wherein the tumor target site has a lowered conductivity.

10. The method of claim 7 , wherein the non-conducting nanoparticle is not a ferroelectric nanoparticle.

11. The method of claim 7 , wherein the site adjacent to the tumor target site has an increased electric impedance.

12. The method of claim 7 , wherein the site adjacent to the tumor target site has a lowered conductivity.

13. The method of claim 7 , wherein the nanoparticles are nanoparticles that increase tissue permittivity.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2024
From: HERSHKOVICH, HADAS; VOLOSHIN-SELA, TALI; BOMZON, ZEEV
To: NOVOCURE GMBH
Reel/Frame 068059/0769 →
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
Continuity (3)
Continuation 17106531 · Nov 30, 2020
Provisional Application 62946798 · Dec 11, 2019
Related Publication 20240207629A1 · Jun 27, 2024
References Cited (53)
US 8892200B2 · Wagner · 2014 [cited by examiner]
US 20080241262A1 · Lee · 2008 [cited by examiner]
US 20100261994A1 · Davalos · 2010 [cited by examiner]
US 20130261683A1 · Soikum · 2013 [cited by examiner]
US 20140121728A1 · Dhillon · 2014 [cited by examiner]
US 20190117973A1 · Schmidt · 2019 [cited by examiner]
US 20200368525A1 · Maag · 2020 [cited by examiner]
MX 2017010319A · 2019 [cited by applicant]
WO WO2019100016A1 · 2019 [cited by examiner]
International Search Report and Written Opinion dated Mar. 9, 2021 for PCT/IB2020/001002, filed Nov. 30, 2020. [cited by applicant]
Agarwal, R. et al., Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms, Proc. Natl. Acad. Sci. U S A 110, 17247-17252 (2013). [cited by applicant]
Armitasari, L. et al., Effect of Polyethylene Glycol (PEG-4000) on Dielectric Properties of Mn0.5Zn0.5Fe2O4 Nanoparticles, 2018 [cited by applicant]
Ballo, M., et al., P01.113 Increasing TTFields dose to the tumor bed improves overall survival in newly diagnosed glioblastoma patients, [cited by applicant]
Branter, J., Basu, S. & Smith, S., Tumour treating fields in a combinational therapeutic approach, Oncotarget 9, 36631-36644 (2018). [cited by applicant]
Chang, E. et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov. 4, 113 (2018). [cited by applicant]
Ciofani, G. et al. Barium titanate nanoparticles: highly cytocompatible dispersions in glycol-chitosan and doxorubicin complexes for cancer therapy. Nanoscale Res. Lett. 5, 1093-1101 (2010). [cited by applicant]
Ciofani, G. et al. Preparation of stable dispersion of barium titanate nanoparticles: potential applications in biomedicine. Colloids Surf. B Biointerfaces 76, 535-543 (2010). [cited by applicant]
Ciofani, G. et al. Effects of barium titanate nanoparticles on proliferation and differentiation of rat mesenchymal stem cells. Colloids Surf. B Biointerfaces 102, 312-320 (2013). [cited by applicant]
Dempsey, C., Coating barium titanate nanoparticles with polyethylenimine improves cellular uptake and allows for coupled imaging and gene delivery, Colloids Surf. B Biointerfaces 112, 108-112 (2013). [cited by applicant]
Fabian, D. et al., Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review, Cancers (Basel) 11, 174 (2019). [cited by applicant]
Genchi, G. G., et al., Barium titanate nanoparticles: promising multitasking vectors in nanomedicine, Nanotechnology 27, 232001 (2016). [cited by applicant]
Giladi, M., et al., Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 14, 54-63 (2014). [cited by applicant]
Giladi, M., et al., Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci. Rep. 5, 18046 (2015). [cited by applicant]
Giladi, M. et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat. Oncol. 12, 206 (2017). [cited by applicant]
Hershkovich, HS, et al., First steps to creating a platform for high throughput simulation of TTFields, Conf. Proc. IEEE Eng Med Biol Soc. Aug. 2016; 2016 :2357-2360. doi: 10.1109/EMBC.2016.7591203. [cited by applicant]
Jamal, A., et al., Characterization of barium titanate prepared via mixed oxide sintering route, J. Pak. Mater. Soc. 2, 91-95 (2008). [cited by applicant]
Jamilpanah, P., et al., Thermal conductivity, viscosity, and electrical conductivity of iron oxide with a cloud fractal structure, Heat Mass Transfer (2017) 53: 1343. https://doi.org/10.1007/s00231-016-1891-5. [cited by applicant]
Jiang, B., et al., Barium titanate at the nanoscale: controlled synthesis and dielectric and ferroelectric properties, Chem. Soc. Rev. 48, 1194-1228 (2019). [cited by applicant]
Jo, Y., et al., Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy, Int. J. Mol. Sci. 19, 3684 (2018). [cited by applicant]
Karanam, N. K., et al., Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung… [cited by applicant]
Kessler, A. F., et al., Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition, Cell Death Discov. 4, 12 (2018). [cited by applicant]
Kim, J.S., et al., CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1, Cancer Res. 73, 6667-6678 (2013). [cited by applicant]
Kim, E. H., et al., Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation, Oncotarget 7, 62267-62279 (2016). [cited by applicant]
Kirson, E. D., et al., Disruption of cancer cell replication by alternating electric fields, Cancer Res. 64, 3288-3295 (2004). [cited by applicant]
Kirson, E. D., et al., (2007), Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors, Proceedings of the National Academy of Sciences of the United States of America, 104(24… [cited by applicant]
Kirson, E. D., et al., Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields), BMC Med. Phys. 9, 1 (2009). [cited by applicant]
Liu R., et al., Nanoparticle-enhanced electrical impedance detection and its potential significance in image tomography, Int J Nanomedicine. 2013; 8:33-8. doi: 10.2147/IJN.S37275. Epub Jan. 3, 2013. [cited by applicant]
Marino, A. et al. Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme. J. Colloid Interface Sci. 538, 449-461 (2019). [cited by applicant]
Mehta, M., et al., Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients, Crit. Rev. Oncol. Hematol. 111, 60-65 (2017). [cited by applicant]
Mun, E. J., et al., Tumor-treating fields: a fourth modality in cancer treatment, Clin. Cancer Res. 24, 266-275 (2018). [cited by applicant]
Ostovari, M., et al., The Effect of Gold Nanoparticles on Electrical Impedance of Tissue on Low Frequency Ranges, J Biomed Phys Eng. Sep. 1, 2018;8(3):241-250. eCollection Sep. 2018. [cited by applicant]
Sadat, Sams M. A., et al., A., Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications, Journal of Biomaterials and Nanobiotechnology 7, 91-108 (2016). [cited by applicant]
Singh, R. & Ulrich, R. K., High and low dielectric constant materials, Interface 8, 26-30 (1999). [cited by applicant]
Sneider, A., et al., Remotely triggered nano-theranostics for cancer applications, Nanotheranostics 1, 1-22 (2017). [cited by applicant]
Stupp, R., et al., NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality, Eur. J. Cancer 48, 2192-2202 (2012). [cited by applicant]
Stupp, R., et al., Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial, JAMA 314, 2535-2543 (2015). [cited by applicant]
Stupp, R., et al., Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial, JAMA 318, 2306-2316 (2017). [cited by applicant]
Swanson, K. D., et al., An overview of alternating electric fields therapy (novottf therapy) for the treatment of malignant glioma, Curr. Neurol. Neurosci. Rep. 16, 8 (2016). [cited by applicant]
Toms, S. A., et al., Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial, J. Neurooncol. 141, 46… [cited by applicant]
Urman, N., et al., P04.57 Creating patient-specific computational head models for the study of tissue-electric field interactions using deformable templates, [cited by applicant]
Voloshin, T. et al. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int. J. Cancer 139, 2850-2858 (2016). [cited by applicant]
Wenger, C., et al., The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study, Phys Med Biol. 2015; 60(18):7339-57. [cited by applicant]
Yoon, Y. N., et al., MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells, BMC Cancer 18, 716 (2018). [cited by applicant]